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Dihydropyridine calcium blockers, rep resented by nifedipine and nicardipine, are widely used for the treatment of hypertensive disorders (1) (2) (3) (4) (5) . However the clinical use fulness of these calcium blockers has been limited by dosage frequency because their durations of action are relatively short (6) . In addition, these compounds induce an acute fall in blood pressure which is ac companied by a counterregulatory increase in heart rate (1, 2, 7).
To eliminate some of these problems, we have synthesized dihydropyridine derivatives and assayed them using conscious SHR, with special attention to the onset and duration of the antihypertensive effect. We describe here the antihypertensive actions of one of these compounds, CS-905, whose chemical structure is shown in Fig. 1 of 30 mg/kg, i.p. The animal was surgically inserted with an aortic cannula via the left femoral artery for measuring blood pressure and heart rate. For the experiments with intravenous administration, the animal was also cannulated into the femoral vein for the injection of drugs. The other ends of the cannulae were led under the skin and ex teriorized at the back of the neck. The rat was placed in an individual cage after surgery and allowed free access to tap water but not to food. When the rats recoverd from surgical stress, normally 2-3 days after surgery, the aortic cannula was connected to a pressure transducer, and blood pressure and heart rate were continuously recorded with a blood pressure measuring system that was de veloped in our laboratories. After blood pres sure and heart rate were stabilized, a single oral dose of CS-905 or nicardipine or a single intravenous dose of CS-905 or nicardipine was given. Blood pressure and heart rate were monitored for up to 24 hr after administration.
Preparation of hypertensive rats
In addition to 14-week-old normotensive Wistar Imamichi rats, the following hyper tensive models were prepared and used in the same manner as SHR for the evaluation of antihypertensive effects of CS-905. 1) Renal hypertensive rats (RHR): Wistar Imamichi rats weighing 130-180 g, 10 weeks old, were used. Renal hypertension was in duced by placing silver clip with an internal split distance of 0.225 mm around the left renal artery. The right renal artery was left intact. The thus made hypertensive rat was designated as the 1 -clip-2-kidney renal hy pertensive rat. Eight weeks after this pro cedure, the animals were cannulated, and experiments were performed in conscious state as described above.
2) DOCA salt hypertensive rats (DOCA salt): A left nephrectomy was performed on 10-week-old male Wistar Imamichi rats that weighed about 100 g. One week after the left nephrectomy, animals were injected weekly with deoxycorticosterone acetate (Sigma, in 0.3% CIVIC solution) and given 1 % saline as drinking water. Sixweeks after DOCA injection when the mean blood pressure reached about 190 mmHg, the animals were cannulated, and experiments were performed in the conscious state as described above. Figure 2 shows the time course of percent changes in mean blood pressure (MBP) and heart rate (HR) after a single oral adminis tration of CS-905 and nicardipine in con scious SH R. Both agents lowered blood pressure in a dose-dependent manner, but there were clear differences in the onset and the duration of action between CS-905 and nicardipine.
Nicardipine produced a rapid decrease of MBP that was accompanied by a great increase in HR, and the durations of MBP and HR before administration of nicardipine were 1 89±3 mmHg and 309±6 beats/min, respectively. Values are means± S.E. from six rats. hypotension were relatively short. On the other hand, CS-905 produced a gradual and long-lasting reduction of MBP with little increase in HR. The sharp increase of H R seen immediately after administration of CS 905 was due to stress given when the drug was orally administered. In fact, the degree of initial tachycardia did not vary with the dose of CS-905 ( Fig. 2A) , whereas the sharp in crease of HR following nicardipine became greater when the dose was increased (Fig.  2B) . The magnitude of the maximum fall in BP produced by CS-905 at 0.3 and 1.0 mg/kg nearly equalled that produced by nicardipine at 1 and 3 mg/kg, respectively. These data suggest that CS-905 was approximately 3 times as potent as nicardipine by oral ad ministration.
CS-905 produced a long-lasting decrease of blood pressure in conscious RHR at doses of 1 and 3 mg/kg, p.o. (Fig. 3A) . The antihy pertensive action in RHR was less than that in SHR ( Figs. 2A and 3A) . In DOCA salt hypertensive rats, whose initial BP was similar to those of SHR and RHR, CS-905 produced a more marked hypotension than in SH R ( Fig. 3B) . The antihypertensive action of CS 905 in normotensive rats was approximately 10 times less potent than that in SHR ( Figs.  2A and 3C ). Figure 4 shows the dose response relation of CS-905 in different animal models of hypertension.
The antihy pertensive action was expressed as the area under the blood pressure curve during the 24 hr observation period. The magnitude of the hypotensive area produced by CS-905 was in the following order: DOCA salt>SHR; RHR>NR.
CS-905 or nicardipine was intravenously administered in conscious SHR (Fig. 5) . A single intravenous administration of nicardi pine produced a rapid fall of MBP, Whereas that of CS-905 produced a gradual and sustained fall of MBP. The magnitudes of the maximum fall in MBP produced by CS-905 at 100 and 300 ag/kg were similar to those produced by nicardipine at 30 and 100 fig/kg, respectively. These data suggest that CS-905 was 3 times less potent than nicardipine by intravenous administration.
Single intraportal venous and intravenous administrations of CS-905 at 30 ug/kg produced similar hypotensions in anesthetized SHR (Fig. 6) . In contrast, a single intraportal venous administration of nicardipine pro duced a much smaller reduction of blood pressure than that produced by intravenous administration of the agent. These data sug gest that nicardipine, but not CS-905, under went the hepatic first pass effect. Figure 7 (A and B) shows the time-course for inhibition of the contractions to 40 mM K+ in rat aorta when CS-905 and nicardipine were acutely applied. Both agents inhibited K+ induced contraction of rat aorta, but there was a marked difference between these agents in the rate of onset of the action. The inhibitory action occurred rapidly with nicar dipine and remained constant within 75 min after the drug was added (Fig. 7B) . On the other hand, the inhibition by CS-905 de veloped very slowly and did not reach a stable level within the 6-hr observation period (Fig.  7A) . We therefore could not compare ac curately the in vitro potencies of the two drugs. Percent inhibition after the 6-hr in cubation period indicates that CS-905 is 3-10 times less potent than nicardipine. The inhibition of K+ contraction produced by 4-hr incubation with CS-905 at 3 nM was abol ished when the Ca" concentration in the bathing solution was raised from 2.5 mM to 25 mM, suggesting that the inhibition was due to a blockade of Ca" entry (data not shown). Figure 8 (A and B) shows the time course for elimination of inhibition of K+ contractions in rat aorta after washout of CS-905 and Values are meansdS.E. from three rats nicardipine. A 40-min exposure to nicardipine (1 or 3 nM) markedly inhibited the contractile response to 40 mM K+. The K+-contraction increased gradually after nicardipine was removed from the bathing solution, and a full sized K+-contraction was obtained within 250 min of washout (Fig. 8B) . In contrast, the 40-min exposure to CS-905 (3, 10 or 30 nM) resulted in a moderate inhibition of K+ con traction. After washout of CS-905, the con tractile response to K+ did not recover but further declined throughout the 6-hr observa tion period. Discussion CS-905 administered orally produced a dose-dependent fall of blood pressure in normotensive and three types of hypertensive rats: SHR, RHR and DOCA salt hypertensive rats (Fig. 4) . The antihypertensive effects of Ca channel antagonists are primarily based on inhibition of transmembrane Ca influx through the voltage-dependent channels of vascular smooth muscles (8, 9). Arteries of DOCA salt hypertensive rats have been shown to have a greater responsiveness to calcium than those of normotensive rats (10). Holloway and Bohr have found that the transmembrane per meability to Ca in the femoral artery of hyper tensive rats differs from that of normotensive rats (11). These reports suggest that one of the major factors contributing to the develop ment of hypertension is an increase in trans membrane permeability to Ca. The degree of the antihypertensive effect produced by a Ca blocker in an animal model would vary with the extent to which the increased Ca permeability of vascular smooth muscle con tributes to the maintenance of hypertension in that particular model. The degree of the antihypertensive effects produced by CS-905 was in the following order: DOCA salt> SHR>RHR>NR (Fig. 4) . Though further studies are needed to clarify the exact me chanisms, one of the reasons for these dif ferent antihypertensive effects may be the difference in the Ca-dependency in the genesis and maintenance of high blood pres sure among these animal models.
It is well-known that nifedipine produces tachycardia both in clinical and experimental situations. This tachycardia is most probably due to baroreceptor reflexes caused by the acute fall of blood pressure (1, 2, 7), because the tachycardia by nifedipine is reduced by prior administration of propranolol (12). In the present study, nicardipine produced an acute hypotension accompanied by a sharp increase in HR, but a single oral administra tion of CS-905 did not increase HR (Fig. 2) . The lack of tachycardia with CS-905 may partly be attributed to the gradual onset of its blood pressure lowering effects because the degree of tachycardia in baroreceptor reflexes is determined not only by the degree of hy potension but also by the rate of blood pressure fall (13).
There are two possible mechanisms that account for the gradual onset of CS-905: first, the absorption of CS-905 from the gastro-intestinal tract is slow (K. Nakamura et al., unpublished data); secondly, the as sociation rates of this compound with the tissue or receptor is slow. The gradual onset of hypotension even after intravenous ad ministration of CS-905 suggest that the second mechanism is the case. Indeed, Ca" channel blockade with CS-905 developed very slowly in the isolated vascular prepara tions as well (Fig. 7) . According to the mem brane approach theory (14), due to the hydrophobic group (diphenylmethylazetidin) at position 3, the CS-905 molecules can only slowly travel in the cell membrane to reach the Ca"-channels.
CS-905, unlike nicardipine, produced long lasting antihypertensive effects. A possible explanation for this long-lasting action of CS-905 is as follows: CS-905 is bound firmly to the calcium channels, and the dissociation rate from calcium channels may be very slow. The results of washout experiments in vitro support this possibility (Fig. 8) .
CS-905 was 3 times more potent than nicardipine on oral administration and was 3 times less potent on intravenous administra tion. This difference may be attributed to the difference in the hepatic decomposition of these two agents. Indeed, the antihyper tensive action of nicardipine administered into the portal vein was much smaller than that after intravenous administration at the same dose (Fig 6) . In contrast, CS-905 produced similar hypotensions by intravenous and intraportal venous administrations (Fig. 6 ). These results indicate that nicardipine under goes hepatic metabolism (the first pass effect) more easily than CS-905.
In conclusion, CS-905 is a potent and long lasting Ca channel antagonist.
By oral ad ministration in conscious SHR, CS-905 was more than three times as potent as nicardipine and its onset of action was gradual, hence producing little increase in HR. The agent produced a hypotension that was greater and longer in hypertensive rats, including DOCA salt, SHR, and RHR, than normotensive rats. CS-905 is expected to be an antihypertensive agent that is effective on a once a day regimen in the clinical situation.
